IDEXX Laboratories, Inc.
General ticker "IDXX" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $42.1B (TTM average)
IDEXX Laboratories, Inc. follows the US Stock Market performance with the rate: 64.3%.
Estimated limits based on current volatility of 1.0%: low 709.36$, high 723.10$
Factors to consider:
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Total employees count: 11000 as of 2024
- US accounted for 65.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Supply chain disruptions, Cybersecurity threats, Geopolitical risks, Public health crises, Labor/talent shortage/retention
- Current price 35.7% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [355.51$, 515.38$]
- 2025-12-31 to 2026-12-31 estimated range: [364.71$, 527.00$]
Financial Metrics affecting the IDXX estimates:
- Negative: with PPE of 36.7 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 28.95 > 18.33
- Negative: negative Industry operating cash flow (median)
- Positive: 42.53 < Shareholder equity ratio, % of 48.44 <= 64.17
- Positive: Interest expense per share per price, % of 0.09 <= 0.74
- Positive: Industry inventory ratio change (median), % of -0.84 <= -0.18
- Positive: Return on assets ratio (scaled to [-100,100]) of 21.23 > 6.04
Short-term IDXX quotes
Long-term IDXX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $3,367.32MM | $3,660.95MM | $3,897.50MM |
| Operating Expenses | $2,468.56MM | $2,563.82MM | $2,769.17MM |
| Operating Income | $898.76MM | $1,097.13MM | $1,128.34MM |
| Non-Operating Income | $-38.79MM | $-35.95MM | $-18.51MM |
| Interest Expense | $39.86MM | $41.58MM | $31.20MM |
| R&D Expense | $254.82MM | $190.95MM | $219.79MM |
| Income(Loss) | $859.97MM | $1,061.18MM | $1,109.83MM |
| Taxes | $180.88MM | $216.13MM | $221.96MM |
| Profit(Loss)* | $679.09MM | $845.04MM | $887.87MM |
| Stockholders Equity | $608.74MM | $1,484.53MM | $1,595.31MM |
| Inventory | $367.82MM | $380.28MM | $381.88MM |
| Assets | $2,746.76MM | $3,259.93MM | $3,293.44MM |
| Operating Cash Flow | $542.98MM | $906.51MM | $929.00MM |
| Capital expenditure | $148.84MM | $133.63MM | $130.92MM |
| Investing Cash Flow | $-195.35MM | $-125.25MM | $-207.06MM |
| Financing Cash Flow | $-370.94MM | $-442.00MM | $-878.07MM |
| Earnings Per Share** | $8.12 | $10.17 | $10.77 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.